---

Iron-Refractory Iron Deficiency Anemia (IRIDA)

---

Definition

• Microcytic, hypochromic anemia
• Complete refractoriness to oral iron therapy
• Slow or partial response to parenteral (intravenous) iron
• Inappropriately elevated hepcidin levels relative to iron stores

---

Genetics

---

Molecular Pathophysiology

Normal Iron Regulation

1. Hepcidin (encoded by HAMP) is the master regulator of systemic iron homeostasis, produced by hepatocytes
2. Hepcidin binds to and induces internalization/degradation of ferroportin (the only known cellular iron export protein), found on duodenal enterocytes and macrophages
3. When hepcidin is elevated: ferroportin is degraded → iron is trapped inside enterocytes and macrophages → less iron enters plasma → iron-restricted erythropoiesis
4. When hepcidin is low (iron-deficient states): ferroportin is upregulated → increased intestinal absorption and macrophage iron release

The BMP-SMAD-HJV Pathway (Hepcidin Activation)

• BMP ligands (particularly BMP6) bind to BMP receptors along with the co-receptor hemojuvelin (HJV) on hepatocyte surfaces
• This activates the SMAD1/5/8 signaling cascade, which enters the nucleus and drives HAMP (hepcidin) gene transcription

Role of Matriptase-2 (TMPRSS6)

• Matriptase-2 is a protease that cleaves HJV from the hepatocyte surface, thereby dampening the BMP-SMAD pathway
• In conditions of iron deficiency, matriptase-2 is upregulated, HJV is cleaved, BMP signaling is reduced, and hepcidin falls - allowing maximum iron absorption
• In IRIDA: loss-of-function mutations in TMPRSS6 → non-functional matriptase-2 → HJV remains intact → BMP-SMAD pathway is constitutively active → inappropriately high hepcidin production even in the face of iron deficiency
• Elevated hepcidin → ferroportin degradation on enterocytes → iron retained within enterocytes, cannot be exported to plasma → functional block of intestinal iron absorption
• Oral iron is absorbed into enterocytes but cannot be exported across the basolateral membrane into the circulation
• IV iron bypasses this block (delivered directly to plasma), explaining the partial response to parenteral iron

---

Clinical Features

Presentation

• Can present at any age from infancy to adulthood, but often detected in childhood or early adulthood
• More severe cases tend to present in infancy/childhood
• Female predominance (due to additional iron demands from menstruation)
• Symptoms of chronic anemia: fatigue, pallor, exercise intolerance, poor growth (in children)
• No response to oral iron supplements - this is the hallmark clinical clue

Physical Examination

• Pallor
• Tachycardia in moderate-severe anemia
• Absence of signs of GI pathology (no malabsorption signs)
• Sometimes associated with alopecia (hair loss) - documented in mouse models and some human cases

---

Laboratory Findings

Diagnostic Biomarker

• A TSAT/hepcidin ratio that is very low strongly suggests IRIDA vs. regular IDA
• In regular IDA: low iron → low hepcidin → TSAT/hepcidin ratio is normal-to-high
• In IRIDA: low iron + high hepcidin → very low TSAT/hepcidin ratio
• Studies show this ratio has an AUC of ~0.88 for discriminating IRIDA from other causes of IDA, as noted in a 2022 study on transferrin saturation/hepcidin ratio discrimination

---

Diagnosis

Diagnostic Criteria

1. Microcytic hypochromic anemia
2. Very low TSAT (often <5%)
3. Low-normal ferritin
4. No/poor response to oral iron (after adequate trial)
5. Partial response to IV iron
6. Elevated hepcidin despite iron deficiency
7. Confirmation: biallelic pathogenic mutations in TMPRSS6 (genetic testing)

Differential Diagnosis

• Hepcidin is inappropriately high (should be low in iron deficiency)
• No response to oral iron despite compliance
• Family history (autosomal recessive - siblings may be affected)
• No identifiable cause of IDA (no GI blood loss, no malabsorption syndrome)

---

Treatment

Intravenous (IV) Iron

• First-line treatment for IRIDA
• Bypasses the blocked intestinal ferroportin, delivering iron directly into plasma
• Common preparations: ferric carboxymaltose, iron sucrose, low-molecular-weight iron dextran
• Response is typically partial - hemoglobin improves but may not normalize
• Repeat dosing is often required (every few months in severe cases)
• Hepcidin remains elevated even after IV iron, so effect is sustained only while iron load is being processed via macrophage recycling pathways

Oral Iron

• Ineffective - do not use as sole therapy
• Some very mild/heterozygous cases may show a partial response to high-dose oral iron, but this is not reliable

Supportive Management

• Folic acid supplementation in some cases
• Address any co-existing nutritional deficiencies
• In women: manage menstrual blood loss to reduce iron demand

Monitoring

• Hemoglobin, ferritin, TSAT at regular intervals
• Hepcidin levels to guide treatment
• Symptom assessment

Emerging/Experimental Therapies

• Anti-hepcidin antibodies / hepcidin antagonists: Block hepcidin action, potentially restoring ferroportin function and iron absorption
• TMPRSS6 upregulators: Theoretically boost matriptase-2 expression; currently experimental
• The same TMPRSS6 pathway is being investigated as a therapeutic target (inhibition) in disorders of iron overload such as beta-thalassemia (to increase hepcidin)

---

Mouse Models

• Tmprss6-knockout mice develop a phenotype closely mirroring human IRIDA: severe microcytic anemia, hepatic hepcidin overexpression, alopecia
• Duodenal enterocytes of knockout mice show decreased basolateral ferroportin protein - iron is retained within enterocytes, confirming the pathomechanism
• Both the anemia and alopecia were rescuable by iron administration in these models

---

Epidemiology and Clinical Relevance

• IRIDA is rare - exact prevalence unknown, but cases reported across multiple ethnicities worldwide
• Often underdiagnosed or misdiagnosed as refractory common IDA
• Patients frequently undergo unnecessary invasive workup (endoscopy, bone marrow biopsy) before the diagnosis is considered
• Recognizing IRIDA prevents costly, unhelpful investigations and directly changes management (oral iron → IV iron)
• TMPRSS6 variants in the general population may contribute to genetic susceptibility to iron deficiency even without full IRIDA - heterozygous carriers may have lower iron stores, especially with co-existing risk factors (menstruation, inflammation, infection)

---

Summary Table

---

1. Entry point - Microcytic, hypochromic anemia with initial iron studies
2. First branch - Confirm typical IDA pattern (low TSAT, low ferritin, high TIBC) vs. other causes of microcytosis (thalassemia, ACD, sideroblastic anemia)
3. Oral iron trial - 3-month adequate-dose trial; good responders exit as common IDA
4. Extended workup - For non-responders: rule out non-compliance, GI blood loss, malabsorption; then measure serum hepcidin and calculate TSAT/hepcidin ratio - the key discriminating step
5. IRIDA confirmation - Inappropriately high hepcidin without inflammation → genetic testing for biallelic TMPRSS6 mutations → confirmed IRIDA → IV iron therapy

• No identifiable cause of IDA after full workup
• Oral iron fails despite compliance
• Hepcidin elevated when it should be suppressed by iron deficiency
• Autosomal recessive family pattern

---

Moderate Acute Malnutrition (MAM) in Children - Detailed Overview

---

1. Definition and Classification

---

2. Global Burden

• ~32.8 million children under 5 years are affected by MAM globally
• In 2022, ~45 million children suffered wasting (6.8% of children under 5), of which ~13.6 million had SAM

• 75% of all wasted children live in Asia; ~22% in Africa

• Over 20% of children under 5 (~148 million) suffer stunting, which overlaps with chronic undernutrition
• MAM is the gateway to SAM - untreated MAM significantly increases risk of progression to SAM and death

---

3. Classification Frameworks

Waterlow Classification (Weight for Height / Height for Age)

---

4. Etiology and Risk Factors

Primary Causes

• Insufficient caloric/protein intake - inadequate food supply, poverty, food insecurity
• Early/inappropriate weaning - transitioning from breast milk to calorie-dense but protein-poor diets (e.g., carbohydrate-only porridge)
• Poor diet quality - monotonous diets lacking micronutrients (zinc, iron, vitamin A)
• Low birth weight / preterm birth - starting with depleted nutritional reserves

Secondary/Contributing Causes

• Recurrent infections - diarrhea, respiratory infections, malaria, measles all increase catabolism and reduce appetite (the malnutrition-infection cycle)
• Intestinal malabsorption - chronic diarrhea, parasitic infections (Giardia, hookworm), celiac disease
• Inadequate breastfeeding practices
• Poor water, sanitation, and hygiene (WASH) - enteric infections and environmental enteropathy
• Maternal malnutrition - in utero programming and poor breast milk composition
• Socioeconomic factors - poverty, food insecurity, displacement (refugees/humanitarian crises), inadequate caregiving

The Malnutrition-Infection Cycle

---

5. Pathophysiology

Protein and Energy Compartments

In MAM (Moderate Wasting / Pre-Marasmic State)

• Caloric deficit develops over weeks to months
• Body mobilizes subcutaneous fat and muscle glycogen as initial energy reserves
• With ongoing deficit, muscle catabolism begins - providing amino acids for gluconeogenesis
• The somatic protein compartment is moderately depleted but not severely
• Visceral protein compartment (albumin) is largely preserved in pure wasting (MAM/marasmus)
• Leptin production falls → stimulates hypothalamic-pituitary-adrenal axis → elevated cortisol → promotes lipolysis and muscle catabolism
• Immune compromise: T-cell mediated immunity is impaired; secretory IgA levels fall; complement components decrease → increased vulnerability to infections
• Gut microbiome alterations have been documented - differences in microbial flora between malnourished and well-nourished children may play a pathogenic role

Comparison of MAM vs Marasmus vs Kwashiorkor

---

6. Clinical Features of MAM

Anthropometric

• Weight-for-height Z-score: -2 to -3
• MUAC: 115-125 mm (in 6 months to 5 years)
• Mid-arm muscle circumference: reduced (reflects somatic protein depletion)
• Skinfold thickness: reduced (reflects fat depletion)

Physical Examination

• General: Child is thin but alert and has preserved appetite (distinguishes from kwashiorkor)
• Skin: Dry, pale, slightly lax; mild scaling
• Hair: May be slightly dull; thin
• Muscles: Visibly reduced bulk, particularly in buttocks, thighs, shoulders
• Subcutaneous fat: Reduced in cheeks, limbs, abdomen
• No edema (presence of edema = SAM by definition)
• No hepatomegaly typically
• May have co-existing micronutrient deficiency signs (angular cheilitis from riboflavin, Bitot's spots from vitamin A, pallor from iron deficiency)

Co-morbidities

• Recurrent diarrhea
• Acute respiratory infections
• Malaria
• Anemia (iron, folate, B12)
• Vitamin A, zinc, iodine deficiencies are common co-morbidities

---

7. Diagnosis

Step 1 - Screening (Community Level)

• MUAC tape measurement: Simple, low-cost, performed by community health workers
  • Green zone: ≥ 125 mm (normal)
  • Yellow zone: 115-125 mm (MAM)
  • Red zone: < 115 mm (SAM)
• Bilateral pitting edema check: Press thumbs on dorsum of both feet for 3 seconds - pitting = SAM (kwashiorkor)

Step 2 - Anthropometric Confirmation (Health Facility)

• Weight-for-height Z-score (WHZ): Requires weight scale and height board; compared against WHO Child Growth Standards 2006
• MUAC: Confirmatory measurement
• Weight for age and height for age to assess stunting alongside wasting

Step 3 - Clinical Assessment

• Full history: dietary intake, breastfeeding, illness episodes, immunization status
• Appetite test (offer RUTF - ready-to-use therapeutic food; good appetite = MAM / poor = SAM indicator)
• Check for bilateral edema
• Signs of infection (fever, respiratory rate, jaundice)
• Examination for micronutrient deficiency signs

Step 4 - Laboratory Tests (if available)

• Hemoglobin / complete blood count (anemia)
• Blood glucose (hypoglycemia risk in SAM but also MAM with illness)
• HIV testing (where indicated)
• Stool microscopy (parasites)
• Malaria RDT (endemic areas)
• Serum albumin (low in kwashiorkor, normal in MAM/marasmus)

Differential Diagnosis of Wasting in Children

• Chronic infection (TB, HIV)
• Malabsorption (celiac disease, cystic fibrosis, giardiasis)
• Congenital heart disease
• Chronic renal disease
• Inflammatory bowel disease
• Endocrine causes (diabetes mellitus type 1)
• Thalassemia / hemolytic anemias

---

8. Management of MAM

Core Principles

Setting

• MAM → Outpatient management (Supplementary Feeding Programme)
• SAM without complications → Outpatient (Community-based Management of Acute Malnutrition - CMAM)
• SAM with complications → Inpatient (Therapeutic Feeding Centre)

Nutritional Treatment

A. Dietary Counselling (All settings)

• Optimize local available foods: animal-source proteins, legumes, fortified cereals, vegetables
• Promote continued breastfeeding in children <2 years
• Increase meal frequency: 5-6 small meals/day
• Improve complementary feeding practices

B. Supplementary Foods (Context-dependent)

• High community prevalence of wasting
• Food insecurity at household/community level
• As part of an integrated care continuum

C. Micronutrient Supplementation

• Vitamin A supplementation (per national schedule; therapeutic dosing if deficiency signs present)
• Iron and folic acid if anemia is confirmed
• Zinc supplementation (especially during diarrheal illness)
• Iodine (via iodized salt)
• Multivitamin formulations in some protocols

D. Treatment of Concurrent Illness

• Antibiotics for confirmed infections (not routinely prophylactic in MAM, unlike SAM)
• Anti-malarial treatment if malaria confirmed
• Antihelminthics (mebendazole/albendazole) if parasitic infection present or in endemic areas
• Oral rehydration for diarrhea
• Vaccination catch-up (especially measles, which causes acute nutritional deterioration)

Modified Dosage Strategy (2023 WHO Innovation)

Community Health Worker (CHW) Role (2023 WHO Endorsement)

---

9. Monitoring Response

Frequency

• Weekly or bi-weekly visits during supplementary feeding

Response Criteria (Discharge from MAM programme)

• WHZ > -2 (or MUAC ≥ 125 mm)
• No bilateral edema
• Minimum stay of 8 weeks (to ensure sustained recovery)
• No acute illness

Failure to Respond (Transfer criteria to SAM programme)

• Deterioration: WHZ falls to < -3 or MUAC < 115 mm
• Development of bilateral edema
• Development of medical complications
• No weight gain after 4 weeks

---

10. Consequences of Untreated MAM

Short-term

• Progression to SAM (2-3x increased risk)
• Increased mortality from common infections (pneumonia, diarrhea, malaria)
• Prolonged hospitalization

Long-term (if MAM occurs in early life)

• Stunting (impaired linear growth) - permanent height deficit
• Neurocognitive impairment - reduced brain development, lower IQ, poor school performance
• Impaired immunity - increased lifetime susceptibility to infection
• Metabolic programming - paradoxically increased risk of obesity, type 2 diabetes, and cardiovascular disease later in life (if high-energy foods given non-selectively during recovery - the "thrifty phenotype" hypothesis)

---

11. Prevention

---

12. Recent Evidence

---

Summary

---

Aicardi Syndrome - Detailed Overview

---

1. Historical Background

• Flexion spasms (infantile spasms)
• Agenesis of the corpus callosum
• Ocular abnormalities (chorioretinal lacunae)

---

2. Genetics and Pathophysiology

Sex Restriction

• Affects almost exclusively females (46,XX)
• Rare cases in 47,XXY (Klinefelter) males have been reported
• Normal (46,XY) males are not affected - believed to be lethal in utero in hemizygous males

Inheritance Pattern

• X-linked dominant - strongly supported by the near-exclusive female prevalence and skewed X-inactivation patterns observed in affected girls
• De novo mutations - virtually all cases are sporadic; familial recurrence is extremely rare
• The causative gene has NOT been identified despite decades of research

Molecular Pathogenesis (2023-2025 Updates)

---

3. Classic Diagnostic Triad

---

4. Ocular Findings (Detailed)

Specific Ocular Features

---

5. Neurological Features

Seizures (Epilepsy)

• Infantile spasms (West syndrome pattern) are the classic seizure type, typically presenting at age 3-5 months
• Seizures are almost universally present and usually severe and refractory to treatment
• Other seizure types occur: focal seizures, tonic seizures, myoclonic seizures, atonic seizures, Lennox-Gastaut pattern
• Seizure control is typically very difficult - polypharmacy is the norm
• Seizures may evolve over time from infantile spasms to other types

EEG Pattern

• Classic EEG finding: Burst-suppression pattern with complete interhemispheric asynchrony - the two hemispheres fire completely independently
• This asynchronous burst-suppression is highly diagnostic in the appropriate clinical context
• After ~6 months of onset: classic EEG may be replaced by multiple epileptic foci with a disorganized background
• Asynchronous sleep spindles after 18 months of age are a good diagnostic clue
• The "batwing" deformity of the third and lateral ventricles is a described radiological-EEG correlate (Adams and Victor's Principles of Neurology)

Brain Malformations (Neuroimaging)

Intellectual Disability

• Present in virtually all cases, typically severe to profound
• Most affected girls have very limited or no purposeful hand use
• Some girls show relative preservation of social engagement despite severe cognitive impairment
• A small subset has milder intellectual disability

Motor and Tone

• Hypotonia in infancy, often followed by spasticity
• Most girls are non-ambulatory
• Feeding difficulties are common (due to hypotonia + neurological dysfunction)

---

6. Systemic Features

Skeletal Anomalies

• Costovertebral abnormalities - vertebral defects (hemivertebrae, butterfly vertebrae, absent/fused ribs), commonly involving thoracic vertebrae
• Scoliosis - progressive; often requiring orthopedic management; can become severe
• Rib anomalies - fused ribs, bifid ribs
• Plain radiographs will show these skeletal changes

Other Systemic Features

• Microcephaly (in some cases)
• Feeding difficulties - gastroesophageal reflux, aspiration risk; gastrostomy tube often required
• Constipation
• Growth delay / short stature
• Skin anomalies - described in some cases (association with MIDAS syndrome - microphthalmia, dermal aplasia, sclerocornea - has been noted in literature)
• Choroid plexus papilloma - reported with increased frequency in Aicardi syndrome (rare brain tumor)

---

7. Diagnosis

Diagnostic Criteria

1. Agenesis of corpus callosum
2. Chorioretinal lacunae
3. Infantile spasms

• Two features of classic triad PLUS at least two major or supporting features

• Cortical malformations (polymicrogyria, heterotopia)
• Periventricular/subcortical grey matter heterotopias
• Interhemispheric cysts
• Optic disc coloboma or hypoplasia
• Other seizure types

• Vertebral/rib anomalies
• Microphthalmia
• Choroid plexus papilloma
• Intellectual disability
• Absent anterior commissure
• Asymmetric cerebral hemispheres

Investigations

Neuroimaging

• Brain MRI (preferred): Shows ACC, interhemispheric cysts, polymicrogyria, heterotopias, hemispheric asymmetry
• Prenatal MRI: A triad of ACC + interhemispheric cysts + polymicrogyria on fetal MRI is a validated highly sensitive predictor of Aicardi syndrome in utero
• CT brain: Less preferred but shows calcifications and gross malformations

Ophthalmology

• Fundoscopy/Indirect ophthalmoscopy under anesthesia if needed to visualize chorioretinal lacunae
• Must be performed by an experienced pediatric ophthalmologist
• Reveals pathognomonic bilateral depigmented lacunae clustered around the disc

EEG

• Video-EEG: Asynchronous burst-suppression between hemispheres is the hallmark
• Later: multifocal discharges with chaotic background

Skeletal Imaging

• Spine X-rays: Vertebral/rib anomalies
• Scoliosis monitoring X-rays (standing/supine)

Genetic Testing

• Chromosomal microarray / chromosomal analysis: Rule out chromosomal abnormalities
• Whole exome/genome sequencing: May identify variants in heterogeneous cases (TEAD1, WNT8B, KMT2B, SZT2, SMARCB1, etc.) but negative result does not exclude diagnosis
• X-inactivation studies: May show skewing, supporting X-linked hypothesis
• Karyotype: Standard chromosomal analysis; identify 47,XXY in rare male cases

---

8. Differential Diagnosis

---

9. Management

Seizure Management

• Anti-seizure medications (ASMs): First-line treatment; polypharmacy almost always required
  • ACTH (adrenocorticotropic hormone) or vigabatrin for infantile spasms (West syndrome protocol)
  • Multiple ASMs trialled: valproate, clonazepam, topiramate, levetiracetam, lamotrigine, phenobarbital
  • Ketogenic diet: Often helpful in refractory epilepsy; should be considered early
  • Vagus nerve stimulation (VNS): May provide partial benefit in refractory seizures
  • Complete seizure freedom is rarely achieved

Ophthalmological Care

• Regular monitoring for retinal detachment
• Management of refractive errors and amblyopia
• Cataract surgery if vision-threatening
• Low vision aids

Developmental and Rehabilitation

• Early intervention programs (physiotherapy, occupational therapy, speech therapy) from infancy
• Augmentative and alternative communication (AAC) for non-verbal children
• Feeding support: Speech therapy for feeding difficulties; consideration of gastrostomy tube (G-tube) if aspiration risk or inadequate nutrition

Orthopedic Management

• Scoliosis surveillance: Regular clinical and radiological monitoring
• Bracing for mild-moderate scoliosis
• Surgical correction (spinal fusion) for severe progressive scoliosis
• Physical therapy to maintain mobility and prevent contractures

Multidisciplinary Team

• Pediatric neurology
• Ophthalmology
• Orthopedic surgery
• Developmental pediatrics
• Physiotherapy + occupational therapy + speech therapy
• Dietitian (ketogenic diet management, nutritional support)
• Genetics counseling
• Palliative care team (for advanced care planning)

---

10. Prognosis

• For individuals who reach age 25, probability of surviving another 5 years is >85%
• Highest mortality risk: Infancy and adolescence
• The Aicardi Syndrome Foundation data suggest median survival potentially exceeding 30 years for survivors of adolescence
• Death typically results from respiratory complications (aspiration pneumonia, status epilepticus, respiratory failure from severe scoliosis)
• Cognitive prognosis: Most affected individuals have profound intellectual disability with very limited functional independence; however, the range is broad - a small minority has milder impairment

---

11. Summary Table

---

---

Microcephaly - Detailed Overview

---

1. Definition

• Severe microcephaly: OFC more than 3 SD below the mean (some define as >3 SD, others >-2 SD on CDC curves)
• Microcephaly vera (true primary microcephaly): Head circumference < 45 cm in adult life (5 SD below mean); brain weight often < 300 g (normal: 1,100-1,500 g)

---

2. Epidemiology

• Prevalence in the US: approximately 1 in 1,150 births (~8.7 per 10,000 live births) per CDC estimates
• In high-income countries generally: 0.3-0.9 per 1,000 newborns
• Higher rates reported in consanguineous populations (autosomal recessive forms more prevalent)
• Higher rates during Zika virus outbreaks in endemic areas (Brazil 2015-2016)
• Can occur as an isolated finding or with other congenital anomalies

---

3. Classification

By Timing of Onset

By Cause

By Proportionality

• Proportionate microcephaly: Small head proportionate to overall small body (may suggest global growth restriction)
• Disproportionate microcephaly: Small head with relatively normal body size (more likely primary brain defect)

---

4. Normal Brain Development (Embryological Basis)

1. The founder population of neural progenitor cells adequately expanding (mitotic spindle integrity is key)
2. Correct neuronal migration to appropriate cortical layers
3. Normal programmed apoptosis (not excessive)
4. Adequate vascular supply and metabolic support

---

5. Etiology

A. Primary (Genetic) Microcephaly

Autosomal Recessive Primary Microcephaly (MCPH)

Other Genetic Causes

B. Secondary (Acquired) Microcephaly

Congenital Infections (TORCH + Zika)

• ZIKV selectively infects radial glia cells (neural progenitors) via the AXL receptor
• Infected progenitors die → massively reduced neuronal output → severe microcephaly
• Also causes centrosomal abnormalities and altered cleavage plane of mitotic radial glia → premature differentiation
• This was confirmed using human iPSC-derived neural organoid models in 2016 studies

Teratogens and Toxic Exposures

Hypoxic-Ischemic and Vascular Causes

• Neonatal hypoxic-ischemic encephalopathy (HIE): Post-natal brain injury → failure of subsequent brain growth
• Placental insufficiency / IUGR: Chronic fetal undernutrition → impaired brain growth
• Stroke / thromboembolism
• Twin-to-twin transfusion syndrome: Vascular steal

Metabolic Causes

• Maternal phenylketonuria (untreated): Elevated maternal phenylalanine is teratogenic
• Congenital disorders of glycosylation (CDG)
• Organic acidemias: Methylmalonic acidemia, propionic acidemia
• Mitochondrial disorders: Impaired energy for neuronal growth
• Aminoacidopathies
• Severe maternal iodine deficiency / hypothyroidism

Other Acquired Causes

• Severe chronic fetal/neonatal malnutrition
• Craniosynostosis (premature suture fusion) - can restrict brain growth secondarily (though craniosynostosis itself is a separate primary cause of small head size via mechanical restriction)

---

6. Neuropathology

In Primary Microcephaly (Microcephaly Vera)

• Brain weight severely reduced (often < 300 g vs normal 1,100-1,500 g)
• Simplified gyral pattern (few primary and secondary sulci - pachygyria or simplified gyri)
• Cerebral cortex: Thick, unlaminated (poorly laminated), grossly deficient in neurons
• Abnormally oriented neurons
• Polymicrogyric cortex in some subtypes
• Forehead: Narrow, receding sharply (anthropoid appearance)
• Face is of normal size - creating a disproportionately small cranium relative to face
• Skull: cranial sutures present, convolutional markings on inner table (brain tried to grow)

In Secondary Microcephaly

• Depends on cause:
  • Periventricular calcifications (CMV, Zika, toxoplasma)
  • Cortical necrosis (ischemia, herpes)
  • White matter loss/gliosis (HIE)
  • Scattered calcifications (toxoplasmosis)
  • Cortical migration defects

---

7. Clinical Features

Head and Facial Appearance

• Small head with OFC ≤ -2 SD (severe: ≤ -3 SD)
• Sloping forehead - narrow, receding
• Prominent ears appearing large relative to small head
• Disproportionately large face compared to small cranium (in microcephaly vera)
• Scalp may appear loose or redundant (skin folds on scalp) in very severe cases
• Premature fontanelle closure may be noted on exam
• Cranial sutures: Present and identifiable (distinguishes from craniosynostosis)

Neurological Features

Sensory Features

• Vision and hearing are spared in primary microcephaly vera (Adams & Victor)
• But secondary causes may cause: visual impairment (CMV chorioretinitis, Zika eye anomalies), sensorineural hearing loss (CMV, rubella)

Associated Systemic Features (Syndromic Cases)

• Scoliosis (in Rett syndrome, various genetic syndromes)
• Short stature (Seckel, MOPD, chromosomal)
• Facial dysmorphism (syndrome-specific)
• Heart defects (trisomy 13/18, rubella)
• Limb anomalies (Fanconi, Cornelia de Lange)
• Skin abnormalities (Angelman, Rett)

---

8. Diagnosis

Step 1 - Accurate Measurement of OFC

• Measure occipitofrontal circumference (OFC) - largest circumference using a non-stretchable tape measure
• Measure on at least two occasions
• Plot against WHO Child Growth Standards (for infants/young children) or CDC growth charts
• Must correct for gestational age in preterm infants
• Compare to parental head circumferences - familial small heads without intellectual disability = familial microcephaly (benign)

Step 2 - Detailed History

• Pregnancy history: Infections (TORCH symptoms, Zika exposure, travel), medications/teratogens, alcohol use, radiation exposure, IUGR
• Birth history: HIE, birth trauma, birth weight, gestational age
• Family history: Consanguinity (AR primary microcephaly), other affected siblings, parental OFC measurements
• Developmental history: Was head normal at birth then stopped growing? (secondary) vs. small at birth (primary)
• Neonatal course: Seizures, jaundice, metabolic crises

Step 3 - Physical Examination

• Complete anthropometrics (head, length, weight)
• Dysmorphic features (syndromes)
• Neurological examination
• Fundoscopy (chorioretinitis - toxo, CMV, Zika)
• Skin examination
• Hearing assessment

Step 4 - Investigations

Neuroimaging

• MRI brain (preferred over CT): Structural brain abnormalities, cortical malformations, migration defects, white matter changes
• CT brain: Calcifications (CMV periventricular, toxoplasmosis scattered, Zika subcortical)
• Prenatal ultrasound: Can detect microcephaly after 20-24 weeks; OFC < 2 SD
• Fetal MRI: More detailed assessment of cortical malformations prenatally

Laboratory Studies

• TORCH serology (IgM and IgG): CMV, toxoplasma, rubella, HSV
• Urine CMV PCR (most sensitive in first 2-3 weeks of life)
• Zika virus PCR / serology (if exposure history)
• Metabolic screen: Amino acids (plasma), organic acids (urine), blood glucose, ammonia, lactate
• Phenylalanine levels (maternal PKU workup if indicated)
• Thyroid function tests

Genetic Testing

• Chromosomal microarray (CMA): High yield in syndromic/multiple anomaly cases; detects copy number variants
• Karyotype: Trisomies, chromosomal rearrangements
• Whole exome sequencing (WES) / Whole genome sequencing (WGS): For suspected monogenic causes; identifies MCPH gene mutations, ASPM, WDR62 etc.
• MECP2 gene sequencing (if Rett syndrome suspected in girls with progressive microcephaly)
• Specific gene panels: If clinical phenotype suggests specific syndrome

Other Tests

• EEG: Baseline seizure characterization; epileptic encephalopathy pattern
• Ophthalmology evaluation: Chorioretinitis, optic nerve hypoplasia, visual acuity
• Audiology: Hearing screen (especially CMV, rubella)
• Echocardiogram: If cardiac anomalies suspected
• Skeletal survey: If skeletal dysplasia features

Prenatal Diagnosis

• Ultrasound with detailed fetal biometry (BPD, HC measurements) from 18-20 weeks
• Fetal MRI from 20-22 weeks: Best detail of cortical development
• Prenatal genetic testing: Amniocentesis or CVS + chromosomal microarray/WES for families with known genetic risk

---

9. Differential Diagnosis

---

10. Management

Seizure Management

• Anti-seizure medications appropriate to seizure type
• EEG-guided therapy
• Consider ketogenic diet for refractory epilepsy

Developmental Support

• Early intervention programs (from birth): Physical therapy, occupational therapy, speech-language therapy
• Physiotherapy: Prevent contractures, maintain mobility
• Augmentative and alternative communication (AAC): For non-verbal or minimally verbal children
• Cognitive stimulation: Special education, adapted learning programs

Feeding Support

• Assess for dysphagia (swallowing assessment)
• Gastrostomy tube (G-tube) if aspiration risk or inadequate oral intake
• Nutritional optimization

Vision and Hearing

• Ophthalmology follow-up: Refraction, amblyopia treatment
• Hearing aids if sensorineural hearing loss (especially CMV, rubella)

Orthopedic Management

• Scoliosis monitoring and management
• Baclofen (oral or intrathecal) for spasticity
• Orthotic devices for positioning

Specific Etiological Treatment

• Congenital CMV: Oral valganciclovir for 6 months in symptomatic neonates - shown to improve hearing and neurodevelopmental outcomes
• Congenital hypothyroidism: Levothyroxine replacement - prevents progressive brain damage if treated early
• PKU: Strict phenylalanine-restricted diet; maternal PKU requires strict dietary control before and throughout pregnancy
• Metabolic disorders: Specific dietary/enzymatic treatment where available

Surveillance

• Regular OFC measurements and growth monitoring
• Developmental surveillance at each visit
• Seizure diary and medication review
• Annual ophthalmology and audiology reviews

Psychosocial Support

• Genetic counseling: Recurrence risk; prenatal diagnosis for subsequent pregnancies
• Family support: Caregiver respite, support groups
• Palliative care input for severe cases

---

11. Prognosis

• Intellectual disability (mild to profound - severity varies widely)
• Epilepsy (frequently refractory)
• Cerebral palsy (especially spastic)
• Visual impairment
• Sensorineural hearing loss (infection-related)
• Behavioral and psychiatric comorbidities

• Severe genetic microcephaly with profound cortical malformations
• Trisomy 13/18 (most die in infancy)
• Severe Zika-associated congenital syndrome with calcifications

---

12. Brain Organoid Research (Cutting Edge)

• Organoids from a CDK5RAP2-mutant patient showed fewer proliferating progenitor cells and premature neural differentiation - directly demonstrating the MCPH mechanism in human tissue
• A CRISPR loss-of-function screen of 173 potential microcephaly genes in organoids discovered novel mechanisms including an endoplasmic reticulum function pathway and extracellular matrix production pathway involved in brain size control
• Zika virus studies using organoids demonstrated AXL-mediated tropism for radial glia, progenitor cell death, TLR3 upregulation, and centrosomal abnormalities - providing the causal link between ZIKV and microcephaly
• Organoid platforms are being used for high-throughput drug screening to identify protective agents against ZIKV microcephaly

---

13. Summary Table

---

---

Neonatal Seizures - Detailed Overview

---

1. Definition

• Almost always acute symptomatic (provoked) - not primary epilepsy
• More common in the first 28 days than at any other time of life
• Manifestations are subtle and atypical due to brain immaturity

• 50% are electrographic-only (subclinical) - detectable only on EEG

• Clinical-EEG dissociation is common (clinical signs may cease while EEG seizures persist)

---

2. Epidemiology

• Incidence: approximately 1-5 per 1,000 live term births; up to 10-15 per 1,000 in preterm infants
• Most common neurological emergency in the newborn period
• Highest risk: preterm neonates, term neonates with perinatal asphyxia
• Represent a manifestation of serious underlying brain pathology in the vast majority

---

3. Pathophysiology

Why Neonates Are Prone to Seizures

GABA Paradox - The Central Mechanism

• NKCC1 (Na-K-Cl cotransporter 1) is highly expressed → accumulates Cl⁻ inside the cell → high intracellular Cl⁻ (~25 mM)
• When GABA_A receptors open → Cl⁻ flows OUT → membrane depolarizes → excitation
• This is the opposite of mature neurons where GABA is inhibitory

• KCC2 (K-Cl cotransporter 2) becomes dominant → extrudes Cl⁻ → low intracellular Cl⁻ (~7 mM)
• GABA_A activation → Cl⁻ flows IN → hyperpolarization → inhibition

Other Factors Contributing to Seizure Susceptibility

• Immature inhibitory interneuron networks - few inhibitory synapses fully established
• Abundant NMDA receptors - excitatory amino acid receptors over-expressed in early development
• More advanced limbic system development compared to cortex → mouthing, eye deviation, apnea as predominant seizure manifestations
• Incomplete corticocortical myelination prevents bihemispheric spread → no generalized tonic-clonic seizures; only focal or subtle seizures
• Incomplete lamination of cortex → less organized and more fragile electrical activity

Consequences of Neonatal Seizures

• Cerebral energy depletion → excitotoxicity → neuronal death
• Suppression of neuronal stem cell proliferation
• Morphological and physiological deficits in the developing brain (shown in animal models)
• In humans: neonatal seizures are independently associated with:
  • Further hypoxic-ischemic brain injury (measured by MR spectroscopy)
  • Later neurodevelopmental impairment
  • Increased risk of epilepsy

---

4. Etiology

Timing Guides Etiology

Major Causes by Category

1. Hypoxic-Ischemic Encephalopathy (HIE) - Most Common

• Accounts for ~50% of neonatal seizures in term infants
• In preterm: HIE + intraventricular hemorrhage each account for ~one-third
• Seizures typically begin 6-24 hours after asphyxia
• EEG shows burst-suppression → progresses to multifocal spikes
• Often associated with other signs: altered tone, encephalopathy, multiorgan dysfunction

2. Intracranial Hemorrhage

• Intraventricular hemorrhage (IVH): Most important in preterm infants (<30 weeks) - accounts for majority of preterm neonatal seizures
• Subarachnoid hemorrhage: Common; often benign "well baby seizures" in term infants
• Subdural hematoma: Birth trauma; large fontanelle, bulging
• Intraparenchymal hemorrhage: Often severe; associated with coagulopathy

3. Metabolic Causes

4. Congenital Infections (TORCH + others)

• Herpes simplex virus (HSV): Day 5-14; focal, refractory seizures; CSF pleocytosis; treat with IV acyclovir urgently
• Cytomegalovirus (CMV): Periventricular calcifications; microcephaly; chorioretinitis
• Toxoplasmosis: Hydrocephalus; scattered calcifications; chorioretinitis
• Group B Streptococcus (GBS) meningitis: Fever; bulging fontanelle; CSF findings
• E. coli meningitis: Similar presentation; gram-negative

5. Inborn Errors of Metabolism (IEM)

6. Congenital Brain Malformations

• Lissencephaly, polymicrogyria, schizencephaly, holoprosencephaly
• Account for 5-10% of neonatal seizures
• Seizures are particularly refractory and typically progress to chronic epilepsy

7. Neonatal Epilepsy Syndromes (Genetic)

8. Perinatal Stroke

• Perinatal arterial ischemic stroke (PAIS): Often presents as focal seizures in otherwise well-appearing term infant; MRI confirms
• Cerebral sinovenous thrombosis (CSVT): Associated with dehydration, polycythemia, infections

9. Drug Withdrawal / Neonatal Abstinence Syndrome (NAS)

• Maternal opioid, benzodiazepine, SSRI use
• Irritability, tremors, sweating, feeding difficulties, seizures
• Seizures typically respond to phenobarbital

10. Polycythemia / Hyperviscosity

• Hematocrit > 65% → sluggish cerebral blood flow → ischemia

---

5. Clinical Classification of Seizure Types

A. By Electroclinical Correlation

B. By Clinical Manifestation

Seizure vs. Jitteriness (Key Differential)

---

6. Diagnosis

Clinical Assessment

• Birth history: Fetal distress, emergency C-section, low Apgar scores, cord blood pH → HIE
• Maternal history: Infections, medications, drug use, diabetes → exposure history
• Family history: Parental seizures → benign familial neonatal epilepsy
• Observation: Video documentation of events is invaluable
• Neurological examination: Tone, responsiveness, fontanelle tension, cranial nerve assessment

EEG - The Gold Standard

• 50% of neonatal seizures are subclinical (electrographic-only)

• Clinical seizure detection is unreliable
• Electroclinical dissociation is common after medication

Conventional EEG findings:

• Burst-suppression: Alternating bursts of activity and flat periods → HIE (severe), Ohtahara syndrome
• Multifocal sharp waves: HIE, metabolic, infection
• Focal sharp/slow waves: Stroke, focal hemorrhage
• Discontinuous theta: Benign neonatal seizures ("fifth-day fits")
• Hypsarrhythmia: In infants evolving to West syndrome
• Interhemispheric asynchrony: Aicardi syndrome (see prior discussion)

aEEG (Amplitude-Integrated EEG):

• Continuous bedside monitoring tool; simplified display
• Detects seizures as sudden rises in the lower amplitude margin
• Less sensitive than full EEG; misses brief or low-amplitude seizures
• Used for ongoing surveillance in NICU

Laboratory Investigations

• Blood glucose (bedside)
• Serum electrolytes: Na, K, Cl, HCO₃, Ca, Mg, phosphate
• Blood gas (metabolic acidosis, pH)
• Full blood count
• Blood cultures (if infection suspected)
• CSF: Cell count, protein, glucose, culture, Gram stain, HSV PCR, enterovirus PCR
• Serum ammonia

• TORCH serology (CMV, toxoplasma, rubella, HSV, Zika)
• Urine CMV PCR (within first 2-3 weeks)
• Serum amino acids
• Urine organic acids
• Urine α-aminoadipic semialdehyde (AASA) - pyridoxine-dependent epilepsy marker
• CSF / serum pipecolic acid
• Lactate (mitochondrial disorders)
• Thyroid function tests

Neuroimaging

Genetic Testing

• Chromosomal microarray: Structural abnormalities, copy number variants
• Gene panels for neonatal epilepsy: KCNQ2, SCN2A, STXBP1, ARX, and others
• Whole exome sequencing (WES): For refractory/unexplained seizures
• Trial of pyridoxine + pyridoxal phosphate + folinic acid should be started empirically in refractory seizures of unknown etiology pending genetic results

---

7. Management

Step 1 - Stabilization (ABCs)

• Airway, breathing, circulation
• Oxygen supplementation; prepare for intubation if needed
• IV access; continuous cardiorespiratory monitoring
• Continuous EEG/aEEG monitoring

Step 2 - Treat Underlying Cause Simultaneously

• Duration > 3 minutes
• ≥ 3 seizures per hour
• Associated with cardiorespiratory compromise

• 3 subclinical seizures on aEEG within 60 minutes

Step 3 - Anti-Seizure Medication (ASM) Protocol

First-Line: Phenobarbital

• Mechanism: GABA_A agonist + NMDA antagonist
• Dose: 20 mg/kg IV over 20 minutes
• Repeat dose: 10 mg/kg if seizures continue; total not to exceed 40 mg/kg without additional agents
• Efficacy: Controls seizures in approximately 50-60% of cases
• Why it may fail: GABA is paradoxically excitatory in immature neurons (NKCC1/KCC2 mechanism)
• Monitoring: Respiratory depression, hypotension; have bag-mask ventilation ready

If Phenobarbital Fails - Second-Line Options

Specific Metabolic Treatments (for refractory seizures of unknown cause)

1. Pyridoxal phosphate (PLP) 30 mg/kg/day divided 3 times daily for 3 days
2. Folinic acid 3-5 mg/kg/day for 3 days
3. Continue if clinical improvement seen, pending genetic results
4. Pyridoxine IV 100 mg with EEG monitoring (beware: can cause apnea)
5. Biotin 10-20 mg/day (biotinidase deficiency)

Step 4 - Therapeutic Hypothermia (for HIE)

• Indicated for term/near-term neonates with moderate-severe HIE
• Core temperature maintained at 33.5°C for 72 hours, then rewarmed slowly
• Reduces death and disability by ~25-30% (NNT ≈ 7-9)
• Seizures are a major indication for monitoring and treatment during cooling

Step 5 - Maintenance Therapy and Weaning

• Seizures resolve with correction of underlying cause → discontinue ASMs before discharge in many cases
• Most neonatologists discontinue phenobarbital before discharge if seizures are resolved and EEG normalized
• Long-term maintenance is reserved for:
  • Structural brain abnormalities with ongoing seizure risk
  • Genetic epilepsy syndromes (KCNQ2, SCN2A, Ohtahara)
  • Abnormal EEG at discharge

---

8. Neonatal Status Epilepticus

• Associated with worse neurodevelopmental outcomes
• Requires escalating treatment through the ASM protocol
• May require continuous midazolam infusion
• Continuous EEG monitoring mandatory
• A 2025 ILAE neonatal task force scoping review has refined criteria for neonatal status epilepticus

---

9. Prognosis

Long-Term Outcomes After Neonatal Seizures

• Epilepsy: 15-30% develop subsequent epilepsy
• Cerebral palsy: 20-30%
• Cognitive impairment / intellectual disability: Variable
• Adverse neurobehavioral outcomes: Neonatal seizures (especially frequent, intractable, or prolonged) are independently associated with later neurodevelopmental impairment beyond the underlying injury

---

10. Summary Table

---